- Home
- NXP vs GOSS Comparison
NXP vs GOSS Comparison
Compare NXP & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXP | GOSS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.2M | 796.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXP | GOSS |
|---|---|---|
| Price | $14.04 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 70.0K | ★ 4.5M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.91 | $0.76 |
| 52 Week High | $14.89 | $3.87 |
Technical Indicators
Market Signals| Indicator | NXP | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 39.59 |
| Support Level | $14.06 | $3.04 |
| Resistance Level | $14.19 | $3.87 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 26.28 | 1.49 |
Price Performance
Historical ComparisonAbout NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.